- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01630226
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland
This is a single center, non-randomized, open label phase II trial to evaluate the clinical and pathologic response of neoadjuvant cisplatin-monotherapy in BRCA1 positive patients. The study will enroll patients with diagnosed breast cancer with a BRCA1 mutation. Patients will be eligible if they have primary breast cancer (measured on mammogram and ultrasound or MRI) and confirmed histological diagnosis of invasive breast cancer by core biopsy. If axilla lymph nodes will be suspected then fine needle aspiration biopsy will be performed. Patients will be drawn from one of three oncology centers: Szczecin, Bielsko-Biała and Kraków.
Patients will obtain staging investigations and will be monitored. Once entry criteria is met and consent obtained, all patients will obtain baseline staging investigation within 3 weeks of trial registration. Routine investigations will include staging scans: mammography, ultrasound of the breast and axilla (assessment of breast tumor and axilla lymph nodes), assessment of chest/abdomen/pelvis (plain film, Computed Tomography [CT] and/or ultrasound as per local standards) and baseline blood work (Complete Blood Count [CBC], electrolytes, creatinine, Liver Function Tests [LFTs], calcium, albumin).
Once staging investigations are complete, all patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy). Clinical response will be evaluated every three weeks by the treating physician while on chemotherapy (tumour of the breast and axilla lymph nodes). After four cycles of chemotherapy the patient will then undergo definitive surgery (mastectomy or breast-conserving surgery). Sentinel lymph nodes procedure will be performed. In case of positive lymph nodes standard lymph nodes surgery will be performed. Pathological complete response will defined as no evidence of residual tumor in the breast and the axilla. There may be evidence of ductal carcinoma in situ. The pathology will reviewed by two independent pathologists.
Following surgery patients will receive standard adjuvant chemotherapy at the discretion of the treating physician and if indicated, the patient will also receive radiotherapy and/or hormonal therapy and/or adjuvant trastuzumab at the description of the treating physician.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tomasz Byrski, MD, PhD
- Phone Number: 48-501-225-501
- Email: tomekbyr@wp.pl
Study Locations
-
-
-
Szczecin, Poland
- Recruiting
- Pomenarian Medical University
-
Contact:
- Tomasz Byrski, MD, PhD
- Phone Number: 48-501-225-501
- Email: tomekbyr@wp.pl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for enrolment into the trial:
- Histologically or cytologically proven diagnosis of invasive breast cancer (stage I-III).
- Documentation of the presence of a germ-line BRCA1 mutation
- Measurable disease of any size by mammography or ultrasound.
- Female diagnosed with breast cancer between the ages of 20 to 70.
- Eastern Cooperative Oncology Group [ECOG] performance status of 0 and 1.
- Evidence of adequate organ function (liver, bone marrow, kidney)
- Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrolment.
- Willingness and ability to comply with scheduled visits, treatment plans laboratory tests, and other study procedures.
- Polish resident.
Exclusion Criteria:
Patients presenting with any of the following will not be included in the trial:
- Previous chemotherapy for current cancer.
- Previous or current diagnosis of any other malignancy except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
- Receiving any medication that may markedly affect renal function.
- Pregnant or breastfeeding women.
- Uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neoadjuvant Cisplatin Chemotherapy
|
Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pathologic Complete Response
Time Frame: Four Months
|
Four Months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Tomasz Byrski, MD, PhD, Pomenarian Medical University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BN-001/83/07-B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BRCA1 Mutation
-
Weill Medical College of Cornell UniversityBasser Research Center for BRCARecruiting
-
University of PennsylvaniaRecruiting
-
Azienda Ospedaliera Universitaria Policlinico Paolo...Unknown
-
Rabin Medical CenterUnknownBRCA1 Gene Mutation | BRCA2 Gene MutationIsrael
-
Memorial Sloan Kettering Cancer CenterUniversity of Pennsylvania; University of California, Los Angeles; Dana-Farber... and other collaboratorsActive, not recruiting
-
Ohio State University Comprehensive Cancer CenterRecruitingBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
-
European Institute of OncologyCompletedBRCA1 Mutation | BRCA2 Mutation | Psychosocial FactorsItaly
-
University of California, San FranciscoAmerican Cancer Society, Inc.CompletedBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
-
University of PennsylvaniaInovio PharmaceuticalsRecruiting
-
nVision MedicalCompletedBRCA1 Mutation | BRCA2 Mutation | Atypia Suspicious for MalignancyUnited States
Clinical Trials on Neoadjuvant Cisplatin Chemotherapy
-
Ankara Etlik City HospitalCompletedBladder Cancer | Bladder Cancer Stage I | Bladder Cancer Stage IITurkey
-
Regina Elena Cancer InstituteRecruitingSurgery | Chemotherapy Effect | Muscle-Invasive Bladder CarcinomaItaly
-
European Organisation for Research and Treatment...UnknownCervical CancerNetherlands, Belgium, Italy, Spain, France, Austria, Portugal, United Kingdom
-
Chinese Academy of SciencesXiangya Hospital of Central South University; Peking University People's Hospital and other collaboratorsRecruitingGastric Cancer | Image | PathologyChina, Italy
-
Rachel MillerCompletedFallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal CarcinomaUnited States
-
Peking University Cancer Hospital & InstituteUnknownQOL; Quality of Life;Gastric Cancer; Gastrectomy;Neoadjuvant ChemotherapyChina
-
Second Affiliated Hospital, School of Medicine,...Leiden University Medical CenterNot yet recruiting
-
Assiut UniversityNot yet recruitingMuscle-Invasive Bladder Carcinoma
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital... and other collaboratorsNot yet recruiting
-
Zhejiang Cancer HospitalUnknownEvaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast CancerChina